MING ZHUANG, XUE ZHANG, LU LI, LIMING WEN, JIAMIN QIN^*

Oncology Research, Vol.32, No.8, pp. 1347-1357, 2024, DOI:10.32604/or.2024.046170

Abstract Hepatocellular carcinoma (HCC) poses a significant threat to human health. Resistance to sorafenib in the chemotherapy of HCC is a common and significant issue that profoundly impacts clinical treatment. While several members of the transmembrane (TMEM) protein family have been implicated in the occurrence and progression of HCC, the association between TMEM39b and HCC remains unexplored. This study revealed a significant overexpression of TMEM39b in HCC, which correlated with a poor prognosis. Subsequent investigation revealed that RAS-selective lethal 3 (RSL3) induced pronounced ferroptosis in HCC, and knocking down the expression of TMEM39b significantly decreased its More >

Wenliang Tan^*†1, Sicong Zhu^*†1, Jun Cao^*†, Lei Zhang^*†, Wenda Li^*†, Kairui Liu^*†, Jinyi Zhong^†, Changzhen Shang^*†, Yajin Chen^*†

Oncology Research, Vol.25, No.9, pp. 1543-1553, 2017, DOI:10.3727/096504017X14886444100783

Abstract Sorafenib has been globally approved as the standard treatment for patients with advanced hepatocellular carcinoma (HCC). However, the response rate of HCC patients to sorafenib is limited because of tumor recurrence and metastasis. Therefore, seeking combined therapeutic strategies with sorafenib is necessary to improve the antitumor efficiency. Here we demonstrated that expression of MMP-2 is positively correlated with the migration ability of HCC cells. Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited… More >

TONG WANG^1,4,#, JINHUAN HONG^1,5,#, JIAJIE XIE^1,5, QIAN LIU⁴, JINRUI YUE^1,5, XUTING HE^1,5, SHIYU GE⁴, TAO LI⁴, GUOXIN LIU⁴, BENZHI CAI^1,3,5, LINQIANG LI^2,*, YE YUAN^1,3,5,*

BIOCELL, Vol.47, No.8, pp. 1811-1820, 2023, DOI:10.32604/biocell.2023.029120

Abstract Background: Phototherapies based on sunlight, infrared, ultraviolet, visible, and laser-based treatments present advantages like high curative effects, small invasion, and negligible adverse reactions in cancer treatment. We aimed to explore the potential therapeutic effects of blue light emitting diode (LED) in human hepatoma cells and decipher the underlying cellular and molecular mechanisms. Methods: Wound healing and transwell assays were employed to probe the inhibition of the invasion and migration of hepatocellular carcinoma cells in the presence of blue LED. The sphere-forming test was used to evaluate the effect of LED blue light irradiation on cancer… More > Graphic Abstract

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1, Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.5, pp. 467-481, 2020, DOI:10.3727/096504020X15925659763817

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

Dong Li^*1, Fei-fan Sun^*1, Dan Wang^*1,Tao Wang^*, Jing-jing Peng^*, Jian-Qiong Feng^*, Hua Li^*, Chao Wang^†, Dai-jun Zhou^*, Hong Luo^*, Zeng-qiang Fu^*, Tao Zhang^*

Oncology Research, Vol.28, No.7-8, pp. 827-828, 2020, DOI:10.3727/096504021X16280937554409

Abstract Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug… More >

Dong Yan^1,#, Chunxiao Li^2,#, Yantong Zhou², Xue Yan¹, Weihua Zhi¹, Haili Qian^2,*, Yue Han^1,*

Oncologie, Vol.24, No.1, pp. 101-111, 2022, DOI:10.32604/oncologie.2022.020357

Abstract Hepatocellular carcinoma (HCC) is one of the most deadly types of cancer. Sorafenib is currently the only available first-line molecular targeted drug approved by the FDA for HCC. However, primary and secondary resistance is often encountered with treatment with sorafenib. Genomic alterations found in HCC represent potential targets to develop new drugs or new combinational strategies against this type of cancer. Here we analyzed genomic alterations from the TCGA database of HCC samples and the corresponding targeted drugs available to the clinic to identify candidate drugs that might hold promise when used in combination with… More >

JIAN XU^1,#, HAILONG GE^1,#, CHEN CHAO¹, FENG MO¹, YU WANG¹, DENGKUI ZHANG¹, XIAOXIAO ZHENG², LI ZHENG², XUEMEI LU², WEI CHEN², QUN XU^1,*, WEIXIN YU^1,*

BIOCELL, Vol.46, No.6, pp. 1493-1503, 2022, DOI:10.32604/biocell.2022.016962

Abstract Although sorafenib has been found to prolong the survival time of patients with hepatocellular carcinoma (HCC), sorafenib resistance remains an important challenge. Increasing studies have demonstrated that long noncoding RNAs (lncRNAs) contribute to drug resistance in a wide number of cancers. Human periodontal ligament stem cell (PDLSC) osteogenesis impairment-related lncRNA (POIR) is a recently defined lncRNA for which little is known regarding its function. Our study aimed to reveal the role of POIR in the development of HCC cell sorafenib resistance. The level of POIR expression in patients and tumor cells was examined by Reverse… More >

AASTHA MITTAL¹, NEELAM MAHALA¹, KOWTHAVARAPU VENKATA KRISHNA², UMA S. DUBEY^1,*, SUNIL KUMAR DUBEY^2,3,*

BIOCELL, Vol.46, No.1, pp. 127-136, 2022, DOI:10.32604/biocell.2021.015932

Abstract Sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma, is limited by its low oral bioavailability. To overcome this drawback, we have developed novel camel milk casein-derived nanoparticles as a drug delivery system. Camel milk casein is not only biocompatible on oral administration but is actually a dietary protein of pharmaceutical relevance. Casein is used because of its amphiphilic nature, self-assembling property, ability to show sustained release, and capability of encapsulating both hydrophilic and hydrophobic drugs. In this study, camel milk casein nanoparticles loaded with sorafenib were developed and characterized. Characterization of casein… More >